Sellas Life Sciences has reached the 80th event in its Phase 3 REGAL trial of Galinpepimut-S for acute myeloid leukemia. The trial is designed to assess the drug's efficacy, with preliminary results anticipated this quarter. Analysts note that prolonged trial durations may enhance the likelihood of failure. The company continues to follow the trial's progress closely, with updates projected as the trial advances. The REGAL trial is a major step in the development of Galinpepimut-S, which has shown positive results in previous phases. Sellas Life Sciences remains dedicated on advancing the drug through the regulatory process, with the goal of bringing a potential treatment to patients with acute myeloid leukemia. The company's thoughtful approach to clinical trials and data analysis is highly regarded in the industry, and investors are watching the trial's outcome with interest.